Unknown

Dataset Information

0

ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.


ABSTRACT: EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression. Moreover, tissue specimens of primary and/or recurrent tumors as well as liver and/or lung metastases of 25 CRC patients having received Cetuximab and/or Panitumumab were examined for the same molecular markers. In vitro and in situ analyses showed that EGFR promoter methylation and EGFR expression as well as the MSI and or CIMP-type status did not guide treatment responses. In fact, EGFR-targeted treatment responses were also observed in RAS exon 2 p.G13 mutated CRC cell lines or CRC cases and were further linked to PIK3CA exon 9 mutations. In contrast, non-response to EGFR-targeted treatment was associated with ATM mutations and low E-cadherin expression. Moreover, down-regulation of E-cadherin by siRNA in otherwise Cetuximab responding E-cadherin positive cells abrogated their response. Hence, we here identify ATM and E-cadherin expression as potential novel supportive predictive markers for EGFR-targeted therapy.

SUBMITTER: Geißler AL 

PROVIDER: S-EPMC5370031 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7163451 | BioStudies
2009-01-01 | S-EPMC2687459 | BioStudies
2019-01-01 | S-EPMC6818206 | BioStudies
2020-01-01 | S-EPMC7140052 | BioStudies
1000-01-01 | S-EPMC5226604 | BioStudies
2018-01-01 | S-EPMC6244225 | BioStudies
2017-01-01 | S-EPMC5604203 | BioStudies
1000-01-01 | S-EPMC5348362 | BioStudies
1000-01-01 | S-EPMC5542236 | BioStudies
2013-01-01 | S-EPMC3596735 | BioStudies